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Abstract
RNA interference (RNAi) provides a powerful new means to inhibit viral infection specifically. However, the selection of
siRNA-resistant viruses is a major concern in the use of RNAi as antiviral therapeutics. In this study, we conducted a lentiviral
vector with a H1-short hairpin RNA (shRNA) expression cassette to deliver small interfering RNAs (siRNAs) into mammalian
cells. Using this vector that also expresses enhanced green fluorescence protein (EGFP) as surrogate marker, stable shRNA-
expressing cell lines were successfully established and the inhibition efficiencies of rationally designed siRNAs targeting to
conserved regions of influenza A virus genome were assessed. The results showed that a siRNA targeting influenza M2 gene
(siM2) potently inhibited viral replication. The siM2 was not only effective for H1N1 virus but also for highly pathogenic
avian influenza virus H5N1. In addition to its M2 inhibition, the siM2 also inhibited NP mRNA accumulation and protein
expression. A long term inhibition effect of the siM2 was demonstrated and the emergence of siRNA-resistant mutants in
influenza quasispecies was not observed. Taken together, our study suggested that M2 gene might be an optimal RNAi
target for antiviral therapy. These findings provide useful information for the development of RNAi-based prophylaxis and
therapy for human influenza virus infection.
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Introduction
Influenza A virus (IAV) remains a scourge on human health
[1,2,3]. Its antigen drifts and shifts are an ever-changing challenge
for available vaccines [4,5]. The appearance of drug resistance is
the main hurdle for the development of antiviral drugs [6,7,8,9].
Given the limitations of current anti-influenza A virus strategies,
the need for novel strategies for prevention and treatment of IAV
is evident [10]. In this regard, RNA interfering (RNAi) technology
holds great promise to inhibit the replication of IAV, including
H5N1 virus.
RNAi is a form of posttranscriptional gene silencing mediated
by short double-stranded RNA, known as small interfering RNA
(siRNA) [11,12]. In this process, the cellular complex Dicer cleaves
a double-stranded RNA (dsRNA) molecule to yield double-
stranded duplexes 21–25 nucleotides in length. These siRNAs
then guide the RNAi induced silencing complex (RISC) to cleave
target mRNAs that share sequence identity with the siRNA
[13,14,15]. Since it was first demonstrated that adding exogenous,
synthetic siRNA molecules to mammalian cells can induce RNAi,
there have been rapidly expanding efforts to develop RNAi
therapies that induce the degradation of target messenger RNA
(mRNA) involved in genetically inherited diseases or acquired
disorders [16,17,18,19,20,21,22].
IAV is an enveloped, negative-stranded RNA virus. The unique
property of single-stranded RNA virus itself makes RNAi an
attractive approach for development of anti-avian influenza
therapeutics. The single-stranded viral genome, consisting of 8
segments contained at least 10 open reading frames (ORFs), serves
as template for both viral genome replication and subgenomic
mRNA synthesis. It has been reported that siRNAs respectively
targeting to the viral genes of polymerase 1 (PB1), polymerase 2
(PB2), polymerase A (PA), nucleocapsid protein (NP), non-
structure proteins (NS1 and NS2), matrix proteins (M1 and M2),
especially those specific for NP, PA and PB1, can potently inhibit
replication of influenza A viruses [16,23,24,25,26]. However, it
has been reported that HIV and HCV may develop siRNA-
resistant mutations quickly [17,27,28], and therefore abrogated
the further RNAi treatment. Thus, the evaluation of long term
inhibition efficiency of designed siRNAs and screening of the
emergence of siRNA resistance mutants are also an important
research target.
In the present study, we identified an effective siRNA targeting
M2 gene (siM2), a highly conserved gene in IAV, as compared to a
reported effective siRNA targeting NP gene (siNP). We further
established cell lines which stably expressing the shRNAs by
transducing lentiviral-shRNA vectors to Madin-Darby cannie
kidney (MDCK) cells. Using these two cell lines, we evaluated long
term antiviral effects of these siRNAs against IAV subtypes H1N1
and H5N1 and further screened the potential siRNA-resistant viral
mutations. Our results showed that rationally designed siM2
conferred long term effective inhibition for IAV replication. It was
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appeared in siM2 targeting sequence even after the virus was
cultured in the shRNA expressing stable cell line for 40 passages.
Results
Screening Effective siRNAs Targeting M2 Gene
Two siRNAs targeting the M2 gene were rationally designed by
siRNA target designer (the sequences of siRNAs are shown in the
supporting information Table S1) and their effect in inhibiting the
virus replication was assessed in MDCK cells. Two siRNAs
targeting the NP gene were included in the experiments as
controls. The results showed the siRNA M-950 exhibited a good
inhibition effect with dose dependent manner, while another
siRNA M-126 just slightly inhibited virus replication even at a
concentration of 100 nM (Fig. 1A). Fig. 1B showed that the siRNA
NP-1496 could inhibit influenza virus replication, while siRNA
NP-336 had no inhibition effect, which is consistent with the
previous report [25].
The siM2 Exhibited Higher Inhibitory Effect of H1N1 Virus
than siNP in Stable Cell Lines
Based on the above results, the lentiviruses expressing the
shRNAs M2-950 or NP-1496 were constructed and transduced
into MDCK cells to establish two stable cell lines, shM2-MDCK
and shNP-MDCK. MDCK cells and the MDCK cells transduced
by blank lentivirus (Mock MDCK) were used as controls. The cell
lines were infected with H1N1 virus at a moi of 0.005 and culture
supernatants were harvested at indicated time-points to determine
the virus titer by plaque assay. As shown in Fig. 2, virus replication
kinetics of Mock MDCK is similar with that of MDCK, indicating
that lentivirus integration didn’t influence virus replication. Virus
titers in shNP- and shM2-MDCK cell cultures were 2 to 10 folds
lower than the controls MDCK and Mock MDCK cultures,
suggesting that virus replication had been suppressed by the
expressed shRNAs in both shM2-MDCK and shNP-MDCK cells.
Notably, siM2 exhibited a better inhibition effect, showing about
2-fold lower viral titer than siNP, although the expression levels of
siM2 and siNP were similar (DCt siM2=6.68, siNP=6.95).
The siM2 Abolished not only M2 mRNA but also siNP
mRNA Accumulation in the Stable Cell Lines
We also measured the accumulation of mRNA for NP and M2
gene in infected MDCK, Mock MDCK, shM2-MDCK and
shNP-MDCK cells. The mRNAs were extracted from the cells
harvested at 1, 2, 4 and 24 hrs post-infection and tested by real-
time RT-PCR. The mRNA expression level is normalized by copy
Figure 1. Effects of chemically synthesized siRNAs on influenza
virus production. (A) siRNA M-950 is effective for influenza virus
inhibition. (B) siRNA NP-1496 can inhibit influenza virus replication at
indicated siRNA concentration. An unrelated siRNA targeting GFP was
used as negative control. MDCK cells were transfected by chemically
synthesized siRNAs, and infected with H1N1 virus at a moi of 0.005 in
8 hrs after transfection. Viral culture supernatants were collected at
48 hrs post infection. The viral load was detected by Q RT-PCR and
expressed by relative viral RNA copies. The data were from three
replicates of the experiments and presented as the mean value+SD.
doi:10.1371/journal.pone.0005671.g001
Figure 2. Inhibition of influenza H1N1 virus production on stable cell lines. Stable cell lines were infected by H1N1 virus at a moi of 0.005.
Virus titer was measured at the indicated time points after infection. Data were from three replicates of the experiments.
doi:10.1371/journal.pone.0005671.g002
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harvested at 4 hrs and 24 hrs post-infection was significantly lower
than those in MDCK, Mock MDCK and shNP-MDCK cells
(Fig. 3A). Similarly, the NP mRNA level in shNP-MDCK cells
collected at 4 hrs and 24 hrs after the viral infection was
significantly suppressed as compared to those in MDCK and
Mock MDCK cells (Fig. 3B). Interestingly, siM2 could also inhibit
the accumulation of NP mRNA (Fig. 3B), suggesting that the siM2
might have a broad inhibition effect.
NP Protein Expression was Suppressed in Virus Infected
shM2-MDCK Cells
To further confirm whether the suppression of NP mRNA in
shM2-MDCK cells indeed affect NP protein expression, the NP
protein level was tested by an indirect immunofluorescence assay.
As shown in Fig. 4, EGFP fluorescence, an indicator of shRNA
expression, was detected in Mock MDCK, shNP-MDCK and
shM2-MDCK but not in MDCK cells, while NP protein was
detected in MDCK and Mock MDCK cells but not in shNP-
MDCK and shM2-MDCK cells. The results were consistent with
above viral mRNA results, indicating that siM2 indeed suppressed
the NP protein expression.
siM2 Provided More Potent anti-H5N1 Viral Effect than
siNP in Stable Cell Lines
We further tested whether siM2 could also inhibit the
replication of a highly pathogenic H5N1 avian influenza virus.
As shown in Fig. 5A, although numbers of plaques were similar in
different MDCK cell lines, smaller size of plaques were only found
in shM2-MDCK cells, suggesting that siM2 inhibited replication
of H5N1 virus. The cell lines were also infected with different
amounts of H5N1 virus and culture supernatants were collected at
different time points to determine the virus titers by HA assay. The
virus replication was significantly inhibited in shM2-MDCK cells
at all time-points, but shNP-MDCK just offered a minor inhibition
effect at early stage of the virus infection (Fig. 5B). These results
further confirmed that siM2 could provide a more potent
protection than siNP against H5N1 infection.
siM2 Resistant Virus Mutant was not Observed Even after
40 Passages
To test if siM2 siRNA-resistant virus mutant would quickly
appeared when cultured in shM2-MDCK cells, H5N1 virus was
continually cultured in shM2-MDCK cells for 40 passages. Every
10 passages, the culture supernatant was collected and tested by
plaque reduction assay. No obvious larger size of plaque was
found. Ten plaques with relative larger size were picked to further
identify potential mutation in the siRNA targeting region by
sequencing. The results showed that no mutation appeared in the
siM2 targeting region even after 40 passages of the cultures (Fig. 6).
Discussion
The principal finding of this study is that rationally designed
siRNA targeting influenza M2 gene (M-950) conferred effective
long term inhibition against influenza A virus replication. Such
high suppressive effect is not only against H1N1 influenza A virus
but also against a highly pathogenic H5N1 subtype. In the
previous related studies, Ge and his co-workers [25] screened
Figure 3. Viral mRNA levels are decreased in stable shRNA-expressing cell lines infected by H1N1. (A) siM2 inhibit M2 specific mRNA
expression level (B)siNP inhibit NP specific mRNA expression level. Stable cell lines were infected by H1N1 at a moi of 0.005, mRNA was isolated at
indicated time after infection. M2 or NP specific mRNA expression level was detected by Q RT-PCR and the results were normalized by copy number
of b-actin. The experiments were repeated three times and the data were presented as the mean values+SD.
doi:10.1371/journal.pone.0005671.g003
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H1N1 virus for 6 hrs and stained with anti-NP antibody. Green represents signal from EGFP in the lentiviral vectors, while red (texas red) represents
staining with anti-NP antibody. Images were taken by using a fluorescence microscope under a 400 magnification. All the pictures were captured
under the same exposure time and gain.
doi:10.1371/journal.pone.0005671.g004
Figure 5. Inhibition of influenza H5N1 virus production on stable shRNA expressing cell lines. (A) Inhibitory effects of siM2 and siNP were
detected by plaque reduction assay after the stable cell lines were infected with 0.05 moi of H5N1 virus for 72 hours. (B) The stable cell lines were
infected with indicated doses of H5N1 virus. Virus titers were measured at the indicated time points after infection. The data were presented as the
mean values of two experiments.
doi:10.1371/journal.pone.0005671.g005
siRNA Long-Term Anti-IAV
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showed that NP-1496 was the best since it can confer a more than
200-folds inhibition of H1N1 virus. Li et al [29] and Tomkines et
al [23] further confirmed that NP-1496 provided high anti-H5N1
effect. We therefore included NP-1496 as a positive control in this
study. Our results showed that siRNA M-950 exhibited similar
(Fig. 1) or even slight higher (Fig. 2) inhibitory effect against IAV
replication as compared to that of NP-1496. A recent report by
Zhou et al [30] also showed that several siRNAs targeting NP and
M genes exhibited effective inhibition against influenza A virus
replication in cultured MDCK cells and in animal models.
However, sequences of their reported siRNAs targeting M2 gene
are completely different from the siRNA M2-950. Furthermore,
chemically synthesized siRNAs or plasmid based shRNAs were
always delivered by transfection in previous related studies,
whereas we used a lentivirus system to deliver selected shRNAs.
Although the integration property of lentivirus has abrogated it to
be used in human, it is helpful for our study purpose to successfully
establish stable cell lines persistently expressing siRNAs.
In this study we found that siM2 not only decreased the level of
M2 mRNA but also the level of NP mRNA, suggesting that siM2
has a broad inhibition manner in the process of influenza virus
replication. Ge et al have reported a similar broad inhibition of
siRNAs [25]. In their study, NP-1496 and PA-2087 provided a
broad inhibition to H1N1 influenza virus, which not only
abolished the accumulations of specific NP or PA mRNAs but
also inhibited the accumulations of mRNAs for M, NS1, PB1, PB2
and PA or NP genes. A possible explanation is that some double
stranded siRNAs may result in IFN responses or activate a RNA
degradation pathway, e.g. Phosphorylated protein Kinase R
(PKR) [9,31,32]. However, the mechanisms of this broad
inhibition of some siRNAs are still not very clear yet. From the
standpoint of viral target choice in RNAi based antiviral therapy,
NP protein is required for elongation and antitermination of
nascent cRNA and vRNA transcripts [33,34]. Without newly
synthesized NP, further viral transcription and replication are
blocked. While, M2 plays a critical role in the assembly of
infectious virus particles. Thus, the potent antiviral effect of siM2
may be attributed to its broad inhibitory effect.
Depending on the stringency of siRNA-target base pairing,
siRNA treatment may cause selection of siRNA-resistant viruses,
and this has been shown with HIV and HCV [17,27,28], and
therefore abrogated the further medication or treatments. Using
lentiviral delivery system, we established stable cell lines
persistently expressing shRNA, which provided a more convenient
experimental approach to study long term inhibition effect of
siRNAs and screen for siRNA resistant virus mutants in
quasispecies in vitro. Our results showed that H5N1 virus cultured
in shM2-MDCK were equally susceptible to siM2 as the original
virus even after 40 passages. Moreover, sequencing of siM2
targeted region in 10 such independent plaque purified virus
isolates revealed sequence identical to the parental one. The
current data have shown no insertion, deletion and nucleotide
substitution in the siRNA target sequence, therefore demonstrated
siM2 possessed good long term inhibition effect for influenza virus
replication without the problem of siRNA resistant mutants.
Taken together, all the findings about effective RNAi target,
lentiviral vector delivery and the establishment of stable shRNA
expressing cell lines in our study provide rational information for
the development of siRNAs as prophylaxis and therapy for
influenza virus infection in humans.
Materials and Methods
Cell lines and viruses
MDCK and Human embryonic kidney 293T cells were
respectively maintained in MEM and DMEM (Invitrogene,
USA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics (100 U penicillin G/mL and 100 ug
streptomycin/mL). Influenza virus strains A/New Caledonia/
20/1999 (H1N1) and A/Hong Kong/486/97 (H5N1) used in
these experiments were prepared in MDCK cells and virus titers
were determined by TCID50. All experiments with H5N1 virus
were performed in BSL-3 laboratory.
Preparation and transfection of siRNAs
The siRNAs targeting M or NP gene of influenza A virus were
designed by siRNA target designer version 1.51 from Promega
(http://www.promega.com/siRNADesigner/program/). The du-
plexes of designed and previously reported siRNAs were
synthesized by Invitrogene (USA) (the sequences were shown in
the supporting information Table S1). The siRNAs were reverse
transfected to MDCK cells using Lipofectamine
TM RNAiMAX
(Invitrogene, USA) as described in company’s instruction. After
Figure 6. Screening for siRNA resistant mutants in shM2-MDCK stable cell line. Influenza A virus was cultured in shM2-MDCK for 40
passages and sequencing of siM2 targeted region in 10 plaque purified virus isolates revealed the parental sequence. P10, P20, P30 and P40 are
representative passages of viruses.
doi:10.1371/journal.pone.0005671.g006
siRNA Long-Term Anti-IAV
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viruses and followed by detection of viral replication. 24 hours
after infection, RNA were extracted from the cells and followed by
real time RT-PCR to detect the relative quantities of replicated
viral RNA.
Construction of lentiviral vectors
The H1-promoter-driven shRNA cassettes were constructed by
annealing two primers containing the 19-nt sense and reverse
complementary targeting sequences with a 9-nucleotide loop -
TTCAAGAGA- and flanking Mlu1 and Cla1 cloning sites (the
sequences of shRNA were shown in the supporting information
Table S1), and then cloned into the 39-end of the H1 promoter in
the LVTHM plasmid [35,36]. The sequences of the insertions
were confirmed by DNA sequencing.
Generation of recombinant lentivirus
Lentiviral vectors with shRNA expression cassette were
produced by calcium phosphate-mediated, three-plasmid trans-
fection of 293T cells [37]. Briefly, 293T cells (2.5610
6 cells in a
75T flask) were transfected with 20 mg LVTHM or LVTHM-
shRNA, 15 mg psAX2 and 6 mg pMD.2G and cultured in DMEM
supplemented with 10% FBS and antibiotics. Virus supernatants
were collected on day 3 post-transfection, filtered through a
0.45 mm pore-size filter, ultracentrifuged at 40,000 g for 3 hrs at
4uC and resuspended in PBS. Virus stocks were titrated by
infecting Hela cells with virus dilutions in DMEM and 8 mg
polybrene (hexadimethrine bromide, Sigma) ml
21 and analyzed
for EGFP expression with a flow cytometer (BD Bioscience
Immunocytometry Systems, USA). Data was processed with
Cellquest software. Titers of the virus stocks were routinely
10
7,10
8 transduction units (TU) ml
21.
Establishment of shRNA expressing stable cell lines
Lentiviral stocks were used to transduce MDCK cells. After 3
days of transduction, the medium containing the lentivirus was
replaced with complete culture medium. The transduced MDCK
was sub-cultured every 3–4 days for 4 weeks to get stable viral
genome integration. Sorting of live GFP positive cells was
performed using a FACStar+ instrument (Becton Dickinson,
USA) [38]. Established stable expressing cell lines were named
as follows: Mock MDCK, MDCK cells transduced by lentivirus
without shRNA insertion; shNP-MDCK, MDCK cells transduced
by lentivirus with shNP insertion (NP-1496); shM2-MDCK,
MDCK cells transduced by lentivirus with shM2 insertion (M-
950). The amounts of shRNAs expression in established lines of
shM2-MDCK and shNP-MDCK were quantified by Q RT-PCR
using forward primers siM2- 59-ACA GCA GAA TGC TGT
GGA T-39 and siNP- 59-GGA TCT TAT TTC TTC GGA G-39,
and the reverse primer provided by Ncode
TM miRNA Q-RT-
PCR kit (Invitrogene, USA) and further calculated with normal-
ized Ct values: DCt (Mock MDCK2shM2-MDCK or shNP-
MDCK).
Influenza virus infection and viral load detection
MDCK and the stable shRNA expressing cell lines in 24-well
plates were infected with viruses at moi of 0.005,0.5 (2 mg/mL
trypsin was used in the infection process of H1N1). After
incubation for 1 hr, the infected medium was removed and
MEM without FBS was added. Cell supernatants were collected at
different time points. The viral load was detected by hemagglu-
tination (HA) and/or plaque assays as described previously [39].
Briefly, the HA assay was carried out in U-bottom 96 well plates.
Serial 2-fold dilutions of virus samples were mixed with an equal
volume of a 0.5% suspension of turkey erythrocytes (Lampire
Biologic Laboratories, Pipersville, USA) and incubated at room
temperature (RT) for 45 mins. Wells containing an adherent,
homogeneous layer of erythrocytes were scored as positive. For
plaque assay, serial 10-fold dilutions of virus sample were added
into a monolayer of MDCK cells. After 1 hr incubation, the virus
was removed and the cultures were overlaid with 1% semi solid
agar-MEM. Three days after infection, plaques were visualized by
staining of crystal violent.
Real-time RT-PCR
Real-time RT-PCR was carried out as described previously
[39]. Briefly, H1N1 or H5N1 virus infected MDCK, Mock
MDCK, shNP-MDCK and shM2-MDCK were harvest at 1, 2, 4
and 24 hr after infection. Total RNA was extracted from the
infected cell samples using RNeasy RNA isolation Kit (Qiagen,
Germany) and reverse transcribed using Superscript II Reverse
Transcriptase and Oligo dT primer (Invitrogene, USA), according
to the manufacturer’s protocol. Viral mRNA copies were
measured by SYBR green M63000 Real-Time PCR System
(Stratagene, USA), using primers NP-Forward: 59-GAC CAG
GAG TGG AGG AAA CA-39, NP-Reverse: 59-CGG CCA TAA
TGG TCA CTC TT-39; M2-Forward: 59-CGT CGC TTT AAA
TAC GGT TTG-39, M2-Reverse: 59- CGT CAA CAT CCA
CAG CAT TC-39 b-Actin-Forward: 59- CGT ACC ACT GGC
ATC GTG AT-59, b-Actin-Reverse: 59-GTG TTG GCG TAC
AGG TCT TTG-39. The reactions were performed at 95uC
10 mins, 40 cycles of 95uC 1 min, 60uC 1 min, 72uC 1 min,
followed by melting curve analysis according to instrument
documentation (Stratagene M63000). All reactions were done in
triplicates and the results were normalized by b-action.
Indirect Immunofluorescence Assay
Indirect immunofluorescence assay was performed as described
previously [40,41] with some modification. MDCK, Mock
MDCK, shNP-MDCK and shM2-MDCK cells grew on micro
cover glasses (Thomas, USA) were infected with 1 moi of H1N1
virus for 6 hrs, After washed with PBS, the cells were fixed in 4%
paraformaldehyde for 15 mins at RT and then permeabilized in
0.1% Triton X-100 for 3 mins at RT. After washed with PBS
again, the cells were incubated with 1:50 diluted mouse anti-NP
antibody (Abcam, UK) for 30 mins in dark at RT. The cells were
washed three times in PBS with 1% FCS and incubated with 1:500
diluted Texas red-conjugated anti-mouse lgG (Abcam, UK) for
30 mins in the dark at RT. The cells were washed and mounted.
Slides were viewed under an Olympus fluorescence microscope
(Olympus, Germany).
Screening siRNA resistant mutants on shM2-MDCK
The screening of potential siRNA resistant mutants were
performed in our established stable shRNA-expressing cell lines
according to previously described protocols [42] with some
modification. Briefly, the shM2-MDCK cells in a T25 cm
2 flask
were infected with H5N1 virus. After cultured for 2 days, the
supernatants were harvested. Part of the supernatants was
inoculated to shM2-MDCK for next passage of the virus culture,
another part was subjected for plaque assay to determine if
potential siRNA-resistant virus appeared. Every 10 passages, ten
bigger size of plaques in the plaque assay were picked for
sequencing to detect any mutation in the siRNA targeting region
using a pair of primers: forward, 59-AAG GCA GAT GGT GCA
GGC AAT-39 and reverse, 59-TAC TCC AGC TCT ATG CTG
ACA-39.
siRNA Long-Term Anti-IAV
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